Curaxis listed on Frankfurt Stock Exchange

Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp. (OTCQB:CURX) (Frankfurt:8CX), today announced Curaxis' new listing on the Frankfurt Stock Exchange (FSE). Curaxis was at the FSE for its opening on February 8, 2011, and will trade under the symbol 8CX:GR.

"We are thrilled to be listed on the Frankfurt Stock Exchange," said Mr. Smith. "As a forward-thinking company, we are among an increasing number of U.S. companies focused on expanding our reach in Europe. This new listing will benefit both Curaxis and our shareholders alike."

The phase IIB clinical trials for Curaxis' lead Alzheimer's drug candidate, Memryte, are anticipated to launch in mid-2011. Memryte addresses the pathologies of Alzheimer's disease through multiple pathways, including beta-amyloid, tau phosphorylation, inflammation and aberrant cell cycling.

"We are very excited to work with Curaxis in Europe. With its stock now listed on the Deutsche Boerse FSE, Curaxis is the only European-traded pure-play drug company with an Alzheimer's drug candidate in advanced FDA trials," said Andreea Porcelli, owner at Luxembourg-based Continental Advisors S.A.

"As Curaxis' U.S. investment banker, we believe the cross-border listing increases liquidity options and creates new strategic partnership opportunities for Curaxis worldwide," added William Schloth, Chief Executive Officer, Southridge Investment Group, LLC.